Entering text into the input field will update the search result below

AbbVie submits risankizumab application to EMA in Crohn's disease

Book about Crohn´s Disease and medication, injection, syringe and pills. Medic concept

Marcelo Ricardo Daros/iStock via Getty Images

  • AbbVie (NYSE:ABBV) has submitted an application to the EMA seeking approval for risankizumab (Skyrizi, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy), an interleukin-23 (IL-23) inhibitor, for the treatment of patients 16 years and older with

Recommended For You

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ABBV--
AbbVie Inc.